Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IR 902 - Immune Response BioPharma

Drug Profile

IR 902 - Immune Response BioPharma

Alternative Names: AI 208; IR-208; Multiple sclerosis vaccine - Immune Response BioPharma; NeuroVax; V beta 17

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune Response Corporation
  • Developer Immune Response BioPharma; Orchestra Therapeutics
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 09 Jul 2019 IR 902 is still in phase II trial for Multiple sclerosis in USA (NDR batch #16)
  • 17 Sep 2018 IR 902 is available on expanded access (Immune Response BioPharma pipeline, September 2018)
  • 12 Aug 2015 Phase-II development for Multiple sclerosis is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top